PCG Molecular – Industry Leading Genetics Diagnostics Company

Partnering to Provide Genetic Diagnostics and Promote Proactive Care

About Us

PCG Molecular in the news

A growing company that is making a difference

PCG Molecular is a preventive care diagnostic company driven to reduce national disease figures and increase survival rates. A proven pioneer in the industry, PCG Molecular is dedicated to the research and development of molecular genetic screening tests that catch problems early, are easy to administer and bring flexible business models to practitioners that promote change.

The 10 year old company that formerly focused primarily on diagnostic work and pathology launched its first molecular genetic screen, the MOP™, in 2012. It is the first comprehensive test of its kind that identifies the early warning signs of oral cancer.

New tests that identify other viruses and precursors of disease are currently in development and are expected to launch in the near future.


Armando Moncada, MD, FCAP

Founder and Chief Medical Officer

Dr. Moncada is the founder of PCG Molecular, Inc., a Molecular/Genetic Information Company focused on fundamentally changing the way cancer patients are screened and treated. PCG Molecular proprietary tests generate actionable molecular/genomic information about patients’ individual cancer risk.

The company’s first clinical product, MOPTM, is the first commercially available comprehensive molecular information product design for use in the routine care of screening for oral (oropharyngeal) carcinoma. Dr. Moncada has received recognition by Worldwide Who’s Who for excellence in medical research. He is a former president of TEXPATH, and an inspector and fellow of the College of American Pathologists and American Academy of Oral Medicine. Dr. Moncada’s areas of expertise include oral cancer genomics, anal cancer molecular/genomics, and GYN molecular/genomics oncogenesis.

Dr. Moncada is a member of the American Medical Association, Association for Molecular Pathology, the Society for Lower Genital Tract Disorders (ASCCP), and the American Society for Clinical Pathology (ASCP). Dr. Moncada, a Honduran-born American Pathologist, received his MD at the National University of Honduras, followed by postgraduate training at Tulane University School of Medicine in New Orleans, Louisiana. He then served as the Medical Director of Hospital Systems in Texas and New Mexico, followed by an appointment as Assistant Professor of Pathology at Baylor College of Medicine in Houston, Texas. When Dr. Moncada is not leading a team of medical/genetics experts, he enjoys playing tennis, horseback riding, playing and practicing Polo, and spending time with his boys.


Corporate Responsibility

Giving Back

the research that may help scientists in the fight

So far there is very little oral cancer screening research that has been done in the United States .  PCG Molecular is in a unique position to promote such studies and drive thought leadership on this topic over the next decade and we are dedicated to serving the scientific community in this way.

We are also dedicated to aiding in the fight for a cure for diseases like oral cancer. Our staff supports various nonprofit organizations working with the diseases we address through volunteer efforts and donations.